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effects of cannabinoids are sustainable during persistent viral infection of the CNS is not
known. Using a rodent model of chronic viral encephalitis based on Borna Disease (BD)
virus, in which 1 week treatment with the general cannabinoid WIN 55,212-2 has been
shown to be neuroprotective (Solbrig et al., 2010), we examine longer term (2 week
treatment) effects of a general (CB1 and CB2) cannabinoid receptor agonist WIN55,212-2
(1 mg/kg ip twice per day) or a speciﬁc (CB2) cannabinoid receptor agonist HU-308 (5 mg/kg
ip once daily) on histopathology, measures of frontostriatal neurogenesis and gliogenesis,
and viral load. We ﬁnd that WIN and HU-308 differ in their ability to protect new BrdUþ
cells. The selective CB2 agonist HU increases BrdU
þ cells in prefrontal cortex (PFC),
signiﬁcantly increases BrdUþ cells in striatum, differentially regulates polydendrocytes
vs. microglia/macrophages, and reduces immune activation at a time WIN-treated rats
appear tolerant to the anti-inﬂammatory effect of their cannabinoid treatment. WIN and
HU had little direct viral effect in PFC and striatum, yet reduced viral signal in
hippocampus. Thus, HU-308 action on CB2 receptors, receptors known to be renewed
during microglia proliferation and action, is a nontolerizing mechanism of controlling CNS
inﬂammation during viral encephalitis by reducing microglia activation, as well as partially
limiting viral infection, and uses a nonpsychotropic cannabinoid agonist.
& 2013 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).2
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. Solbrig).1. Introduction
Neuroinﬂammation is recognized as early event or key acceler-
ant in the pathobiology of persistent CNS infections, HIVassociated cognitive decline, prion diseases, and neurodegenera-
tive diseases such as Alzheimer's, Parkinson's and Huntington's
Diseases. The discovery of cannabinoid receptors, identiﬁcation
of their naturally occurring ligands, and increase in
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cannabinoid (endocannabinoid) system, has advanced the
exploration of cannabinoid receptor compounds for novel
CNS therapies (Piomelli, 2003, Mechoulam and Parker, 2013).
The CB1 receptor is abundant in the brain (Howlett et al.,
2002), signals progenitor cells, neurogenesis and develop-
ment (Aguado et al., 2007, Diaz-Alonso et al., 2012), can be
neuroprotective, and mediates many of the psychoactive
effects of cannabinoids (Mackie, 2005, Monory et al., 2007).
The CB2 receptor is present mainly on immune cells of both
the periphery and CNS (Howlett et al., 2002). Its activation is
immunomodulatory, regulatory and neuroprotective (Atwood
and Mackie, 2010), through reduction of microglia/macro-
phage activation, migration (Romero-Sandoval et al., 2009,
Fraga et al., 2011), and decrease in proinﬂammatory cytokines
and toxins (Cabral and Grifﬁn-Thomas, 2009, Bouchard et al.,
2012). That CB2 expression increases in disease states asso-
ciated with neural inﬂammation (Benito et al., 2008, Pacher and
Mechoulam, 2011) adds to its appeal as a therapeutic target.
Borna Disease Virus (BDV) is a veterinary pathogen causing
encephalitic illnesses in a variety of mammalian and bird hosts
(Lipkin and Briese, 2007). In experimental species it provides an
informative model for study of persistent CNS infections.
Experimental Borna Disease, based on well-characterized
rodent models of viral-induced neuroinﬂammation and
degeneration and dependant on host strain, genetics and
age of exposure, is used for study of acute and chronic CNS
infections and their treatments. Male Lewis rats infected at
adolescence develop persistent infection, inﬂammation and
regional neurodegeneration (Narayan et al., 1983, Solbrig et al.,
1994, Planz et al., 1995). One week treatment of adolescent-
infected Lewis rats (BD rats) by the general cannabinoid agonist
WIN55,212-2 (with CB1 and CB2 receptor activity) limits reactive
gliogenesis and macrophage activity in favor of new cell,
particularly oligodendroglia, development. The neuroprotective
effect depends on restricting microglial activation and is
independent of endocannabinoid (anandamide, 2-AG) levels
and antiviral effect (Solbrig et al., 2010).
Here, we test the efﬁcacy of the general cannabinoid agonist
WIN 55,212-2 and compare it with the more speciﬁc CB2 agonist
HU-308 as adjunctive long-term therapy in chronic viral ence-
phalitis. Since CB2 receptors are upregulated in response to
lesion or inﬂammation in a variety of cell types (Cabral and
Grifﬁn-Thomas, 2009), are known to be renewed during micro-
glia proliferation and action (Maresz et al., 2005, Racz et al.,
2008), and inhibit populations of microglia/macrophages after
neural injuries (Zarruk et al., 2012), we test the speciﬁc hypoth-
esis that administration of a selective CB2 agonist provides
sustained neuroprotective and anti-inﬂammatory effects.2. Results
BrdU immunohistochemistry (IHC) was used to quantify 14
day old BrdUþ cells, a measure of precursor cell survival. PFC
subﬁelds, or the striatum plus subventricular zone (SVZ),
were combined for quantitative analysis. BrdU cell counts in
both regions were signiﬁcantly decreased in BD rats com-
pared to NL uninfected rats [BD vs. NL po0.001]. BrdU counts
in PFC and striatum of BD rats were unchanged by WIN [forPFC BD vs. BDþWIN p40.05 Tukey's post hoc following
signiﬁcant ANOVA F(3,16)¼64.46 po0.0001; for striatum BD
vs. BDþWIN p40.05 Tukey's post hoc following signiﬁcant
ANOVA F(3,16)¼48.30 po0.0001] (Experiment 1)(Fig. 1A).
Double label IHC with cell-type speciﬁc markers were used
to evaluate phenotype of new cells. ED1 antibody, which
recognizes an antigen in lysosomal membranes of phagocytes,
is expressed by activated microglia and the majority of tissue
macrophages (Bauer et al., 1994). Here, ED1 antibody with BrdU
labeling would identify newly generated cells of microglia/
macrophage lineage and phagocytosed BrdU cells. Each of the
BD groups was compared to NLs. When percentages of NG2/
BrdU, GFAP/BrdU, NeuN/BrdU and ED1/BrdU colabeled cells
were compared, the greatest changes were signiﬁcant
increases in percentage of ED1 double labeled cells, in BD and
BDþWIN animals [PFC BD vs. NL χ2¼33.92 po0.0001 BDþWIN
vs. NL χ2¼16.22 po0.0001; Striatum BD vs. NL χ2¼38.10
po0.0001 BDþWIN vs. NL χ2¼13.32 p¼0.0003] (Fig. 1B). Many
other ED1þ/BrdU-cells surrounded BrdUþ cells in perivascular
locations in both untreated BD and BDþWIN animals (Fig. 1C).
Histologic similarities between the groups, distinct from reduc-
tions in ED1þ cells after 1 treatment week (Solbrig et al., 2010),
showed that, beyond 1 treatment week, WIN-treated rats were
insensitive to WIN's anti-inﬂammatory effect.
Because of lack of efﬁcacy of WIN, our next experiment
(Experiment 2) examined the effects of 2 week treatment with
a selective CB2 agonist HU-308 on new cells and histopathol-
ogy, testing the hypothesis that a CB2 agonist prevents or
delays loss of cannabinoid neuroprotective and anti-
inﬂammatory effects. Double label IHC with BrdU and cell
type speciﬁc markers was performed and compared with
WIN-treated animals. HU-308 and WIN differ in their ability
to protect new cells, as shown by increased numbers of BrdUþ
cells in PFC of HU-treated BD rats [BUþHU 4671þ718 vs.
BDþWIN 2837þ451, t(1,7)¼2.258, p¼0.058] and signiﬁcantly
increased numbers of BrdUþ cells in striatum of HU-treated
BD rats [BDþHU 12,360þ1447 vs. BDþWIN 8114þ954, t(1,8)¼
2.448, po0.05] (n¼4–5 group) (Fig. 2A) along with signiﬁcant
increases in percentages of NG2/BrdU cells in BDþHU animals
[PFC BDþHU vs. BDþWIN χ2¼9.524 p¼0.0020; Striatum
BDþHU vs. BDþWIN χ2¼15.74 po0.0001 (n¼4–5 group)]
(Fig. 2B). At least one HU target was ED1 cells. HU-treated
BD rats had more signiﬁcant reductions in percentages of
ED1/BrdU colabeled cells in both regions [PFC BD vs. BDþWIN
χ2¼2.40 p40.05; BD vs. BDþHU χ2¼11.48 p¼0.0007; Striatum
BD vs. BDþWIN χ2¼9.765 p¼0.0018; BD vs. BDþHU χ2¼15.72
po0.0001 (n¼4–5 per group)] (Fig. 3A) and HU was superior to
WIN in reducing inﬂammatory histopathology (Fig. 3B).
To determine cellular localization of CB2 receptors in BD
rat brain, double label IHC studies using antibodies to CB2
receptors, and markers for activated microglia/macrophages
(ED1), T cells (CD3) and astroglia (GFAP) and neurons (NeuN)
were performed. CB2 receptor immunoreactivity in patterns
that were mainly membrane or submembrane, was present
on inﬂammatory and glial cells of untreated BD rats (Fig. 4).
Cells were identiﬁed as activated microglia, astrocytes, or T
cells based on cell marker immunostaining, morphology and
location, conﬁrming receptor presence with inﬂammation
and immune activation during BD viral encephalitis. Delicate
staining outside the double-labeled cell was interpreted as
Fig. 1 – Two weeks of WIN treatment fails to protect newborn cells. (A) There were signiﬁcant decreases in numbers of BrdUþ
cells in BD rats compared to NL uninfected rats in both PFC and striatum. There were comparable decreases in BrdUþ cells in
WIN-treated BD rats (nnnpo0.001 vs. NL, npo0.05 vs. NL)(Tukey's post hoc following signiﬁcant ANOVA n¼4–5 per group) and
increases in WIN-treated NL rats (npo0.05 vs. NL). Data expressed as mean7SEM. (B) There were signiﬁcant increases in
percentage of BrdU/ED1 double labeled cells in both BD and BDþWIN animals (nnnpo0.001 vs. NL, expressed as percent double
labeled cells with each cell type speciﬁc marker and analyzed by χ2 n¼4 per group; NS indicates not signiﬁcant).
Representative single Z plane (0.50 μm thick) confocal images illustrate immunoreactive cells positive for BrdU/NG2, BrdU/
GFAP, BrdU/NeuN or BrdU/ED1 in striatum of BD rats (red BrdU; green cell marker; scale bar¼10 μm). (C) ED1 immunoreactive
macrophages or activated microglia, present in both BD and BDþWIN animals and absent from NLs, contribute to a local
microenvironment deleterious to young cell survival (striatal sections, scale bar¼50 μm).
b r a i n r e s e a r c h 1 5 3 7 ( 2 0 1 3 ) 2 7 3 – 2 8 2 275punctate staining of cross sections of cellular processs. Over-
all the highest immunoreactivity (IR) was cell-associated at
meningeal edges and perivascular locations. Blood vessels of
BD rats showed intense signal at outer surface walls while
sparse CB2 staining was associated with blood vessels in
uninfected brains (not pictured).
CB2 receptors were targets of HU, with patterns of CB2
receptor-like IR altered by treatment (Fig. 5). Diffuse (basal)
CB2 receptor staining in untreated BD brains and irregulargranular patterns of CB2 receptor-like immunoreactivity (IR)
in WIN-treated brains were seen. In contrast, CB2 receptor-
like immunoreactivity (IR) appeared as coarse inclusions or
clusters compressed within the cell, a pattern consistent with
internalization of receptors during agonist exposure. Fewer
meningeal CB2R-IR cells were found in this group.
To test a direct viral effect of WIN or HU, levels of
bornaviral N (nucleoprotein) segment RNA were measured
by qRT-PCR of BD, BDþWIN, BDþHU rats (n¼7 per group)
Fig. 2 – WIN and HU308 differ in their effects on numbers
and phenotype of new cells. (A) There were increases in
numbers of BrdUþ cells in PFC, signiﬁcant increases in
numbers of BrdUþ cells in striatum in BDþHU rats compared
to BDþWIN rats (npo0.05, data expressed as mean7SEM).
(B) signiﬁcant increases in percentages of NG2/BrdU cells in
BDþHU animals (χ2 nnpo0.01 nnnpo0.001)(n¼4–5 group).
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(Experiment 3).
Regional quantities of viral RNA, expressed as copies
vRNA/μg tissue and reported as mean7SEM, were
Striatum [BD 1.56310670.209106; BDþWIN
1.12910670.145106; BDþHU 1.11210670.305106 F
(2,18)¼1.236 p40.05].
PFC [BD 5.08310670.120106; BDþWIN 2.421067
0.615106; BDþHU 2.72310670.127106 F(2,18)¼1.849
p40.05].
Hippocampus [BD 2.54010670.307106; BDþWIN 1.038
10670.201106; BDþHU 1.42410670.489106 F(2,18)¼
4.882 po0.05 BD vs. BDþWIN po0.05 Tukey's post hoc following
signiﬁcant ANOVA] (n¼7 per group).
Signiﬁcant numeric reductions in copies vRNA/μg tissue in
hippocampus of animals treated with WIN were found, along
with vRNA reductions in hippocampus of HU treated subjects.
In PFC and striatum, where within group variability was high,
WIN and HU had no statistically signiﬁcant effects on vRNA.
There was no clear association between virus and either pro-
or anti-inﬂammatory effects across the 3 groups. Overall,
a useful anti-inﬂammatory effect without detrimental increase
in virus had been achieved by HU treatment.3. Discussion
Testing the effects of synthetic cannabinoids as adjunctive
therapy in chronic viral encephalitis, we found the speciﬁc
CB2 receptor agonist HU-308 superior to the general cannabi-
noid agonist WIN55,212-2 in providing longer term anti-
inﬂammatory effects and preservation of newborn cells.The anti-inﬂammatory action was through mechanisms
involving glial cells, in particular CB2 receptor agonist sup-
pression of microglia activation. Modest antiviral effects were
produced by both HU-308 and WIN55,212-2.
Whereas one week treatment with WIN had protected
against inﬂammatory-mediated new cell loss in a previous
study (Solbrig et al., 2010), the effect was not found when
treatment was extended for 2 weeks. Histologic similarities in
inﬂammation and lack of new cell protection between WIN-
treated and drug-naive BD rats after 2 weeks treatment were
interpreted as BD rats showing tolerance to WIN's anti-
inﬂammatory effect, limiting the efﬁcacy of the general
cannabinoid agonist WIN to sometime between 1 and 2
weeks of treatment. In other words, WIN had produced
decreasing effect with repeated dosing. Mechanisms of toler-
ance to WIN could include saturation or downregulation of
CB1 receptors, uncoupling CB1 stimulation from progenitor
cell or neuron biologic processes of protection, or uncoupling
CB1 stimulation from control elements in immunologic
effects in the CNS and periphery.
To achieve long term anti-inﬂammatory efﬁcacy and new
cell protection, a strategy of selective CB2 receptor stimulation
was chosen, based on known coordinated responses of the
endocannabinoid system to injury. Speciﬁcally, local endocan-
nabinoid levels increase with tissue injury or inﬂammation
(Franklin et al., 2003, Walter et al., 2003) at the same time as CB2
receptors on inﬂammatory and some parenchymal cells are
induced by immune cell transcription factors or soluble inﬂam-
matory factors. IFNγ and granulocyte macrophage-colony sti-
mulating factor (GM-CSF) promote CB2 expression in microglia
(Maresz et al., 2005, Racz et al., 2008) while stimulation of CB2
receptors reduces microglia migration (Romero-Sandoval et al.,
2009) production of TNF-α (Sagredo et al., 2009, Zarruk et al.,
2012), reactive oxygen species (Han et al., 2009), and regulates
expression of iNOS and CCR2 (Racz et al., 2008). This constant
supply of CB2 receptors, renewed during microglia proliferation
and action, represented a druggable potentially nontolerizing
target for long term inﬂammation reduction.
In our experiments, the anti-inﬂammatory action achieved
with HU-308 was through mechanisms involving glial cells,
mainly activated microglia, in which CB2 receptors were
upregulated in response to neural injury. Finding CB2
receptor-like IR on microglia was altered by HU treatment in
patterns consistent with receptor internalization, while lack of
receptor internalization by WIN maintained microglia and
active morphology, raise the possibility of functional selectiv-
ity or biased agonism between these 2 synthetic cannabinoid
ligands. Internalization of CB2 receptors to different extents
with different agonists, differential activation of speciﬁc down-
stream signaling pathways, and the inability of WIN stimula-
tion to internalize CB2 receptors, are all effects that have been
shown in vitro (Atwood et al., 2012).
The differential effects of WIN and HU also may relate to
the mixed or more promiscuous pharmacologic effects of
WIN. Although WIN and HU have similar in vitro binding
afﬁnity to CB2 (Pertwee, 2010), WIN is an aminoalkylindole
with signiﬁcant agonist activity at CB1, CB2, and the vanilloid
receptor VR1; HU-308 is a bicyclic compound and a selective
CB2 agonist (Pertwee, 2010); and TRPV1 (transient receptor
potential vanilloid 1 receptor) activation is proinﬂammatory.
Fig. 3 – WIN and HU308 differ in their ability to protect new cells. (A) Double label IHC with cell type speciﬁc markers showed
more signiﬁcant percent reductions of BrdU/ED1 colabeled cells were in HU-treated animals (Analyzed using χ2 npo0.05
nnpo0.01 nnnpo0.001 vs. BD; n¼4 per group). Data expressed as mean7SEM. (B) In representative striatal sections, advanced
pathology of a drug-naïve BD rat is shown with an engulfed BrdUþ cell (top, arrow) and nearly complete phagolysosome
digestion of BrdUþ material by ED1 cells (line 2, arrow). Intermediate pathology in a WIN-treated animal is illustrated by an
early step in enclosure of BrdUþ cell (left arrow) by ED1þ cell together with a second intact BrdUþ cell (right arrow, line 3).
Less advanced pathology is indicated by lower overall ED1þ staining and preservation of BrdUþ cells (lower panel, arrows) in
an HU-treated animal. (scale¼10 μm).
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Fig. 4 – CB2 receptor immunoreactivity is present on inﬂammatory and glial cells. Double label immunoﬂuorescence for CB2R
and cell speciﬁc markers show CB2R-IR on parenchymal ED1þ cells (activated microglia/macrophages) of striatum (A, D),
perivascular CD3þ cells (T lymphocytes) near meningeal surface (v vessel, m meninges) of PFC (B, E), and GFAPþ (astrocytes)
in subventricular zone (svz) of striatum of BD rats. Arrows indicate CB2R antibody staining. Sections are shown at low (A, B, C)
and high (D, E, F) magniﬁcation. The top panel is photographed with Olympus BX51 ﬂuorescent/brightﬁeld microscope;
scale¼20 μm; lower panel with Olympus FluoView Laser Scanning Confocal Microscope; scale¼10 μm. High power views of
microglia and astrocytes show shortened hypertrophic processes consistent with activated microglia and reactive astrocytes.
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tors of inﬂammatory pain in dorsal spinal cord, with a role in
neuron-mediated glial activation in primary sensory ganglia
of rodents (Chen et al., 2009, Cavanaugh et al., 2011). In rat
TRPV1 is also expressed in astrocytes and microglia (Doly
et al., 2004, Kim et al., 2006). That TRPV1 cation channel
activity has been shown in vitro to upregulate microglial
reactive oxygen species production by induction and/or
maintenance of NADPH oxidase activity (Schilling and Eder,
2010, 2011), connects WIN to inﬂammation.
The interaction of cannabinoids and viral infection has
been studied in vitro, in animal models, and in individuals
with infections with recreational or medicinal use of canna-
binoids. Cannabinoids worsen disease when inﬂammatory
and cell-directed antiviral responses required for viral clear-
ance are reduced, with HSV-2, Kaposi's sarcoma herpesvirus
KSHV, Vesicular stomatitis virus VSV, HCV, Coxpox, HIV,
and SIV as examples (reviewed in Reiss, 2010). On the other
hand, cannabinoids beneﬁt disease when host inﬂammatory
response is associated with pathology, not recovery, e.g.
Theiler's murine virus TMV (reviewed in Reiss, 2010), BDV
(Solbrig and Hermanowicz, 2008, Solbrig et al., 2010), also HIV
and SIV (Molina et al., 2010, 2011, reviewed in Rom and
Persidsky, 2013)
Important contributions to understanding cannabinoid/
viral interactions are from the expanding experimental evi-
dence of direct effects of cannabinoids on retroviral replica-
tion. Viral replication in immune tissues is reduced in CB2
agonist treated microglia (Rock et al., 2007) or in THC treated
animals with SIV where suppression of viral replication is
a consequence of suppressed inﬂammation (Molina et al.,
2011). Molecular mechanisms underlying the protectiveeffects of cannabinoids and involving HIV's replication
machinery are decreased HIV-1 LTR activation by CB2 ligands
in HIV-infected macrophages (Ramirez et al., 2013). Structural
mechanisms of viral reduction are alterations of cytoskeletal
architecture of resting CD4þ T cells by CB2 R agonism, where
reducing F-actin levels inhibit actin reorganization and
impair productive infection (Costantino et al., 2012).
Important contributions to understanding cannabinoid/
viral disease interactions and disease modulation are emer-
ging from experimental literature on SIV disease. Chronic
Δ-9-THC IM treatment of SIVmac251 infected rhesus mon-
keys decreased serum and CSF viral load and tissue inﬂam-
mation, reduced morbidity and mortality (Molina et al., 2010).
As a result, further investigations are focusing on stress/
immune system integration and contributions of genome-
wide transcriptional modulation and epigenetic factors to the
cannabinoid-associated disease phenotype. Differential reg-
ulation of several genes in the NFkB system, a signaling
system linked to virulence factors such as enhanced viral
replication, host cell survival, immune response and inva-
sion, has been described (Molina et al., 2011).
As in other viral systems, interpretation of cannabinoid
treatment effects on BDV is complicated because of the variety
of interactions between virus and inﬂammation. For example,
reduced viral load might decrease inﬂammation or alterna-
tively, reduced viral load could be a consequence of a more
robust inﬂammatory response. Of structures studied, the stria-
tum, with its brain parenchyma still largely intact at this stage
of infection, has the potential to most clearly render cannabi-
noid effects in the BD rat. The striatum is infected later than
PFC and hippocampus (Solbrig et al., 1994, 1998), has less
neovascularization and tissue remodeling (Solbrig et al., 2010),
Fig. 5 – Qualitative patterns of CB2 receptor immunoreactivity (IR) were altered by treatment, consistent with agonist-induced
receptor internalization in BDþHU rats. Double immunoﬂuorescence staining of CB2 receptors and ED1 cells had a diffuse
pattern of CB2 receptor staining that, in untreated BD rats, approximate the contours or edge of the cell (top panels). In WIN-
treated rats (middle), a slightly more organized or compressed pattern of CB2R-IR was found. In contrast, HU treatment
promoted receptor internalization, seen as consolidated or packaged CB2 IR material within the cell (lower). Arrows indicate
CB2R-IR. (scale bar¼10 μm).
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We see “same virus, more pathology”, for example, increased
ED1 staining per microscopic ﬁeld in striatum of WIN and BD
rats compared to HU-treated rats. Thus, in striatum, a structure
normalized for virus, degree of inﬂammatory neuropathology is
a reﬂection of anti-inﬂammatory efﬁcacy of a drug treatment,
not virus. In PFC, where neuropathology appears more
advanced and vRNA numbers more divergent, there was no
clear association between virus and either pro- or anti-
inﬂammatory effects across the 3 groups. And ﬁnally, in
hippocampus, HU produced a modest reduction in vRNA,
with the mechanism of effect on virus not known. The
multiple factors involved in Borna Disease expression and
progression under cannabinoid treatment cannot be comple-
tely reconciled using a single in vivo system, and a systematic
approach integrated across several experimental domains
will be required.
Our current results introduce the possibility that CB2 R
agonist-induced changes at cellular, tissue, or systems
level could have a role in reducing productive infections byBDV, may be generalizable to other neurotropic viruses,
and provide a mechanism of neuroprotection beyond reduc-
tion of inﬂammation. Our results also improve upon past trials
managing BDV encephalitis in rats with aggressive immuno-
suppressive therapy that resulted in dissemination and unu-
sual distribution of virus beyond the CNS (Stitz et al., 1991).4. Conclusion
In summary, upregulation of CB2 expression under different
pathophysiological conditions has been reported in several
experimental paradigms and disease states with inﬂamma-
tory or degenerative processes, diseases that have in com-
mon glial activation, inﬂammation, oxidative/nitrative stress,
and degeneration. Targeting of CB2 receptors with selective
agonists is a new therapeutic avenue in inﬂammatory degen-
erative disorders for reduction of neuroinﬂammation. Our
experiments show HU-308 activation of CB2 receptors, recep-
tors known to be renewed during microglia proliferation and
b r a i n r e s e a r c h 1 5 3 7 ( 2 0 1 3 ) 2 7 3 – 2 8 2280action, is a nontolerizing mechanism of controlling CNS
inﬂammation during viral encephalitis and uses a nonpsy-
chotropic cannabinoid agonist. Contrast with WIN will help
inform decisions in use of newly developed cannabinoid
agonists as accessory therapy.5. Experimental procedures
5.1. Animals
Male Lewis rats (Charles River Labs, Wilmington, MA, USA)
were group housed on a 12 h light–dark cycle with ad libitum
access to food and water. All experimental procedures were
performed in compliance with the institutional (University of
Manitoba) and Policy for the Humane Care and Use of
Laboratory Animals guidelines. Under isoﬂuorane anesthesia,
4-week old males were infected with Borna Disease virus (BD
rats) by intracerebral injection of 1.6104 tissue culture
infectious dose units, strain He/80, or sham-infected with
sterile phosphate buffered saline (NL rats).5.2. Drugs
Experimental rats received three 50 mg/kg ip injections of the
S phase marker 5-bromo-2′-deoxyuridine (BrdU) (Sigma St
Louis MO USA) at 6 h intervals at 5 weeks of age (postnatal
day 34) (Solbrig et al., 2010). BrdU incorporation was followed
by 2 weeks of treatment with the non-selective cannabinoid
receptor agonist R(þ)-WIN 55,212-2 (WIN) (Sigma, St Louis,
MO USA) (1 mg/kg ip twice a day) or vehicle (saline) control
(from postnatal day 35 to postnatal day 48) (Experiment 1) or
followed by 2 weeks of treatment with the selective canna-
binoid receptor 2 (CB2) agonist HU-308 (Tocris/R&D Systems,
Minneapolis, MN, USA) (5 mg/kg ip once a day) or vehicle
(Tween-80: DMSO:saline 1:1:18 ) control (Experiment 2). The
HU-308 dose was selected based on demonstration of striatal
neuroprotection in a rodent model of Huntington's Disease
(Sagredo et al., 2008).Table 1 – Antibodies used for cell idenitiﬁcation.
Detection target Cell characteristic 11 Antib
BrdU New cells Rat mon
BrdU New cells Mouse m
NG2 Glial precursors Rabbit p
GFAP Astrocytes Rabbit p
GFAP Astrocytes Mouse m
NeuN Neuronal lineage Mouse m
CD68(ED1) Activated microglia macrophages Mouse m
CB2 Cannabidoid 2 receptor cells Rabbit p
CD3 T lymphocytes Mouse m
21 Antib
Biotinyl
Alexa Fl
Alexa Fl5.3. BrdU quantiﬁcation, imaging and analysis
Animals were sacriﬁced, brains removed and processed as
described (Solbrig et al., 2010) BrdU immunohistochemistry
was performed to quantify 14 day old BrdUþ cells, a measure
of precursor cell survival in PFC and striatum. These areas were
chosen for morphologic studies because of their role on
behavioral deﬁcits of experimental BD (Solbrig et al., 1994, 1996).
Forty-micrometer sections were collected on a freezing
microtome with the left and right hemispheres of every sixth
section slide-mounted. For BrdUþ cell quantiﬁcation, the
following PFC subregions: orbitofrontal cortex, anterior cin-
gulate, prelimbic cortex and infralimbic cortex, were included
from Bregma þ4.20 to Bregma þ2.70 mm (Paxinos and
Watson, 1998). Striatal and subventricular regions were
included from Bregma þ2.50 mm to Bregma 0.80 mm. Sec-
tions were processed for BrdU immunostaining with primary
(1:400, Chemicon, Billerica, MA, USA) and biotinylated sec-
ondary antibodies (1:200 Vector Burlingame, CA, USA), devel-
oped with 3,3′-diaminobenzidine, and quantiﬁed as described
(Solbrig et al., 2010)(n¼4–5 per group).
Double label IHC with cell-type speciﬁc markers were used
to evaluate phenotype of new cells (Table 1). (Primary anti-
bodies were omitted in controls for staining). A one-in-six
series of sections were processed for BrdU immunostaining
(1:100, Accurate, Westbury, NY, USA), cell type markers, or
CB2 receptors 2 weeks after the BrdU injection.
Antigens were visualized with Alexa-488 or Alexa-546
secondary antibodies (1:1000, Molecular Probes Carlsbad,
CA, USA). Colocalization of antibodies was assessed with an
Olympus FluoView Laser Scanning Confocal Microscope at
600 using multitrack scanning and an optical section
thickness of 0.50 μm in the Z-plane as described (Solbrig
et al., 2010) (n¼4 per group). Data were expressed as percen-
tage of double labeled cells for BrdU and each cell marker
examined.
5.4. Virus measurements
A separate group of BD animals (n¼7 per experimental group)
were infected at 4 weeks of age and treated from postnatal
day 35 to postnatal day 48 with WIN, HU or vehicle, as above.
Levels of bornaviral N (nucleoprotein) segment RNA wereody Catalog Source
oclonal 1:100 OBT0030 AbD serotec
onoclonal 1:400 (DAB) MAB3424 Millipore
olyclonal 1:250 AB5320 Millipore
olyclonal 1:50 Z-0334 abcam
onoclonal 1:2000 ab4648 Dako Cytomation
onoclonal 1:500 MAB377 Millipore
onoclonal 1:100 MCA341GA AbD serotec
olyclonal 1:500 sc-25494 Santa Cruz
onoclonal 1:100 ab82251 abcam
ody Source
ated IgG (HþL) 1:100 Vector
uor 546 IgG (HþL) 1:1000 Life Technologies
uor 488 IgG (HþL) 1:1000 Life Technologies
b r a i n r e s e a r c h 1 5 3 7 ( 2 0 1 3 ) 2 7 3 – 2 8 2 281measured by qRT-PCR of BD, BDþWIN, BDþHU rats in each of
3 regions: PFC, striatum, and hippocampus (Experiment 3).
Previous study has shown RT-PCR quantiﬁcation correlates
with measurements of viral burden by focus forming unit
assays (Solbrig et al., 2002). The hippocampus was added
because it is a structure reliably infected early in disease in
this model.
Brain regions were dissected as described (Solbrig et al.,
1994, 2002, 2006) and total RNA was extracted using RNEasy
Plus Universal Extraction System (Qiagen, Toronto, ON)
according to manufacturer's instructions. Frozen tissues were
weighed, homogenized in 150 μl Qiazol Lysis Agent with
sterile disposable RNase/DNase-free pestles, brought to
volume with Qiazol Lysis Agent, further disrupted by tritura-
tion. Viral RNA was eluted from silica columns with 40μl
RNase free water containing 0.5 U/μl RNase Out (Invitrogen/
Life Technologies, Burlington, ON), and placed in 5 μl aliquots.
Quantitative RT-PCR was conducted with a LightCycler 480
(Roche, Laval, QC) using the QuantiFast Pathogen RT-PCRþIC
system (Qiagen) with primer set p40bobe-286R(GCA CCC CTC
CGT GAA CAA)/p40bobe-187F(CAG TCA CGG CGC GAT ATG T),
per manufacturer's instructions. Reverse transcription was
conducted at 50 1C, followed by 45 cycles annealing/elonga-
tion at 60 1C and melting at 95 1C. Probe p40bobe-247T (6Fam-
ATC CCA GGA CTG CAC GCT GCG TT-BBQ) (TIBMolbiol,
Adelphia, NJ) was used to detect ampliﬁed product (Solbrig
et al., 2002). Serial log dilutions (102–108) of a known
positive stock extract were included in each assay for quan-
tiﬁcation of vRNA. Absolute quantiﬁcation with 2nd deriva-
tive maximum was established using the LightCycler 480
programming, and copies vRNA/μg tissue were determined.5.5. Data analysis
Numeric data are represented as meanþSEM and are con-
sidered signiﬁcant if po0.05. Statistical analysis was per-
formed using Student's t tests (for comparisons of two
groups) or one-way ANOVA followed by Tukey's post hoc test
(for more than 2 groups). To compare co-expression of
various markers in BrdUþ cells, the percentage or propor-
tional data for differences in treatment groups, set in 22
tables, were analyzed by Chi square test with Yate's correc-
tion. All analyses were carried out with the GraphPad Soft-
ware (San Diego, CA, USA).Acknowledgments
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